Meeting
2023 ASCO Annual Meeting
PSMAddition: A phase 3 trial to compare treatment with 177Lu-PSMA-617 plus standard of care (SoC) and SoC alone in patients with metastatic hormone-sensitive prostate cancer.
Authors
Scott T. Tagawa
Weill Cornell Medicine, New York, NY
Scott T. Tagawa , A. Oliver Sartor , Fred Saad , Alison Helen Reid , Olga V. Sakharova , Felix Y Feng , Karim Fizazi , Michael J. Morris
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Genitourinary Cancer—Prostate, Testicular, and Penile
Track
Genitourinary Cancer—Prostate, Testicular, and Penile
Sub Track
Prostate Cancer– Advanced/Hormone-Sensitive
Clinical Trial Registration Number
NCT04720157
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr TPS5116)
DOI
10.1200/JCO.2023.41.16_suppl.TPS5116
Abstract #
TPS5116
Poster Bd #
201a
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Genitourinary Cancers Symposium
PSMAddition: A phase 3 trial to compare treatment with 177Lu-PSMA-617 plus standard of care (SOC) versus SOC alone in patients with metastatic hormone-sensitive prostate cancer.
First Author: A. Oliver Sartor
Poster
2023 ASCO Annual Meeting
Prostate-specific membrane antigen ligand positron emission tomography (PSMA-PET) disease extent and overall survival (OS) in patients (pts) with high-risk nonmetastatic castration-resistant prostate cancer (nmCRPC): An international multicenter retrospective study.
First Author: Boris A. Hadaschik
Poster
2024 ASCO Genitourinary Cancers Symposium
Utility of PSMA PET/CT for imaging ductal carcinoma of the prostate.
First Author: Ahmed M. Mahmoud
Poster
2024 ASCO Genitourinary Cancers Symposium
SABRE: Assessment of safety and efficacy of 64Cu-SAR-BBN in patients with PSMA-negative biochemical recurrent prostate cancer.
First Author: Luke T. Nordquist